Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: There is concern that immune checkpoint inhibitors (ICPIs) can provoke relapses in people with multiple sclerosis (pwMS).
Objective: Analyze outcomes of pwMS who received ICPI treatment for malignancy.
Methods: We electronically identified pwMS who received ICPI treatment at Mass General Brigham hospital system. We retrospectively obtained information about patients' MS, cancer, treatment, and outcomes.
Results: Sixteen patients were identified with an average (standard deviation (SD)) age of 67.4 (11.9) years. Eleven (68.8%) had no relapses since MS diagnosis. None had MS relapses after ICPI treatment or new MS lesions.
Conclusion: ICPI use was not associated with increased clinical disease activity in this cohort of older patients with inactive MS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/13524585221117949 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application study of pressure- and volume-controllable balloon in direct visualisation interstitial cystitis dilation surgery.
Int Urol Nephrol
August 2025
, Dalian, China.
Objective: This study aimed to evaluate the efficacy and safety of pressure- and volume-controlled balloon dilation in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) and to compare it with traditional bladder hydrodistension to explore a superior therapeutic approach.
Methods: A prospective randomised-controlled trial was conducted, enrolling 50 women with IC/BPS aged 52-77 years, treated between July 2013 and June 2023. Patients were randomly assigned to a pressure- and volume-controlled balloon dilation group (experimental group, n = 25) or a traditional bladder hydrodistension group (control group, n = 25).
Pharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality.
Nefrologia (Engl Ed)
August 2025
Division of Nephrology, Department of Medicine, Instituto Português de Oncologia do Porto, FG, E.P.E., Porto, Portugal.
Introduction And Objectives: Acute kidney injury (AKI) is a frequent and severe complication in hospitalised cancer patients. However, overall data from in-hospital drug-related AKI in cancer patients is scarce. We aim to review the profile of moderate to severe drug-induced AKI in patients admitted to an oncology hospital over the last two decades and to assess renal and overall outcomes.
View Article and Find Full Text PDFOptimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?
Acta Oncol
July 2025
General Medical Oncology, University Hospital Leuven, Leuven, Belgium.
Background And Purpose: Optimal treatment duration is unknown in metastatic renal cell carcinoma (mRCC) responding to immune checkpoint inhibitors (ICPIs). Prolonged treatment can lead to late toxicity, burden for day clinics and financial impact.
Patients And Methods: This multicenter retrospective study included mRCC patients responding to ipilimumab/nivolumab in first-line or nivolumab in later lines, who were treated for at least 21 months and did not stop for toxicity.
The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review.
Immunotherapy
August 2025
Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
Hepatocellular carcinoma (HCC) often presents at an advanced stage, limiting treatment options. Historically, systemic therapies like tyrosine kinase inhibitors and VEGF-targeted antibodies offered modest survival benefits. HCC's immunosuppressive microenvironment, driven by regulatory T cells, myeloid-derived suppressor cells, and immune checkpoint signaling, hinders effective therapy.
View Article and Find Full Text PDFCross-organ examination of hematologic toxicities from immune checkpoint inhibitors: insights from real-world data.
Jpn J Clin Oncol
July 2025
Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-shi, Osaka, 541-8567, Japan.
Objective: Immune checkpoint inhibitors (ICPis) are widely used clinically to improve the prognosis of various cancers. However, little is known about their hematologic immune-related adverse events (irAEs). This study aimed to comprehensively investigate the incidence and clinical characteristics of irAEs induced by ICPis through a cross-organ research approach.
View Article and Find Full Text PDF